Lion Point Capital, LP Kiniksa Pharmaceuticals, Ltd. Transaction History

Lion Point Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$10.44 - $16.48 $179,056 - $282,648	17,151 Added 15.11%	130,691 $1.84 Million
Q1 2023 May 15, 2023	SELL	$10.7 - $15.79 $2.49 Million - $3.68 Million	-232,960 Reduced 67.23%	113,540 $1.22 Million
Q4 2022 Feb 14, 2023	SELL	$11.42 - $17.05 $1.52 Million - $2.28 Million	-133,500 Reduced 27.81%	346,500 $5.19 Million
Q1 2022 May 16, 2022	BUY	$9.3 - $12.37 $3.95 Million - $5.26 Million	425,000 Added 772.73%	480,000 $4.77 Million
Q4 2021 Feb 14, 2022	SELL	$10.39 - $15.15 $4.58 Million - $6.68 Million	-440,748 Reduced 88.91%	55,000 $647,000
Q1 2020 May 15, 2020	BUY	$11.0 - $19.76 $5.45 Million - $9.8 Million	495,748 New	495,748 $7.67 Million

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Lion Point Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Lion Point Capital, LP with notifications on news.